Olivia Brayer

“And, yeah, we'll definitely be missing Amit and David going forward. Can you guys talk about the strategies that you have in place to engage with emergency services, just as we think about EMTs?”

“First one on Zilsudme launch dynamics, are you guys seeing an increase in prescriptions that are being written that maybe just aren't yet translating into filled prescriptions?”

“I also wanted to give a quick thanks to Sarah for all her help and contributions over the year. On Bryn Supri, given how strong the launch has been, has anything changed in how you guys are thinking about the addressable patient population?”

“For that second half data disclosure, can I just clarify that you guys plan to break out tolerability and efficacy for those 40 patients specifically in the optimization cohort?”

“Shauna, I know you aren't necessarily breaking things out yet by individual treatment line, but anything you can tell us about how many lines of therapy, the confirmed partial responses that you had in that 8.6 and 10 mg per kg cohorts?”